West Panmure outperform on Novartis
WestLB Panmure has upgraded its rating on Novartis increasing from neutral to outperform with a target price of 70 Swiss francs per share. At this moment, the title of Swiss pharmaceutical company is gaining 0.26%, the leadership of the team hope that the verdict of the merchant bank will give credit to a title strongly penalized in the last three months of the year.